<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>356</serviceExecutionTime><Drug id="81757"><DrugName>E-10D</DrugName><DrugSynonyms><Name><Value>E-10D</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1059755">Guangzhou Dabo Biological Products Co Ltd</CompanyOriginator><CompaniesSecondary><Company id="1059755">Guangzhou Dabo Biological Products Co Ltd</Company><Company id="25421">Kobe University</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1059755" type="Company"><TargetEntity id="5035555271" type="organizationId">Guangzhou Sonyn Biological Technology Co Ltd</TargetEntity></SourceEntity><SourceEntity id="25421" type="Company"><TargetEntity id="4296007338" type="organizationId">Kobe University</TargetEntity></SourceEntity><SourceEntity id="799" type="ciIndication"><TargetEntity id="C56" type="ICD10"></TargetEntity><TargetEntity id="10033128" type="MEDDRA"></TargetEntity><TargetEntity id="D010051" type="MeSH"></TargetEntity><TargetEntity id="-1370909262" type="omicsDisease"></TargetEntity><TargetEntity id="626" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="799">Ovary tumor</Indication></IndicationsSecondary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="805">Folate modulator</Action><Action id="4780">Adenovirus based gene therapy</Action></ActionsSecondary><Technologies><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="62">Virus recombinant</Technology></Technologies><LastModificationDate>2017-08-29T08:34:55.000Z</LastModificationDate><ChangeDateLast>2016-04-29T00:00:00.000Z</ChangeDateLast><AddedDate>2012-11-07T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1059755" linkType="Company"&gt;Guangzhou Doublle Bioproducts&lt;/ulink&gt;, in collaboration with   &lt;ulink linkID="25421" linkType="Company"&gt;Kobe University&lt;/ulink&gt;, was investigating a  recombinant  adenovirus (E-10D), targeting folic acid, for the potential injectable treatment of ovarian cancer. In November 2012, the program was in preclinical studies [&lt;ulink linkID="1337671" linkType="Reference"&gt;1337671&lt;/ulink&gt;]. In December 2014, the program was listed on Guangzhou's website [&lt;ulink linkID="1621717" linkType="Reference"&gt;1621717&lt;/ulink&gt;]. In December 2015, the project was no longer listed on the company's website [&lt;ulink linkID="1718811" linkType="Reference"&gt;1718811&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="25421">Kobe University</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="799">Ovary tumor</Indication><StatusDate>2015-12-07T00:00:00.000Z</StatusDate><Source id="1718811" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1059755">Guangzhou Dabo Biological Products Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="799">Ovary tumor</Indication><StatusDate>2015-12-07T00:00:00.000Z</StatusDate><Source id="1718811" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1059755">Guangzhou Dabo Biological Products Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2012-11-06T00:00:00.000Z</StatusDate><Source id="1337671" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25421">Kobe University</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2012-11-06T00:00:00.000Z</StatusDate><Source id="1337671" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1059755">Guangzhou Dabo Biological Products Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="25421">Kobe University</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="144177" title="Guangzhou Doublle Bioproducts and Kobe University to codevelop E-10D for ovarian cancer "/></Deals><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>